The Fifth Annual International Conference on Frontiers in Cancer Prevention Research is the pre-eminent cancer prevention research meeting in the world, where you can learn about the latest translational discoveries from the leading basic, clinical, epidemiologic, and behavioral scientists in the field. Attendance at this comprehensive conference is the most efficient single way to keep current in our rapidly advancing field. Over 850 scientists, clinicians, cancer survivors and advocates, and other professionals will be in attendance, and over 430 posters will be presented.
Highlighting a program of extraordinary presentations, Dr. Judah Folkman of Harvard University will give the Distinguished Lecture on targeting the angiogenic switch in prevention, and Sir Richard Peto of Oxford University will give the Keynote Address on the worldwide hazards of smoking.
We are pleased to announce that the Fifth Annual AACR-Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research Lecture will be delivered by Dr. Stephen S. Hecht. The rich variety of session formats includes educational, organ site, plenary, and poster sessions. Exciting topical sessions will target tissue injury and inflammation; epigenomics, imprinting, and stem cells; nutrition, physical activity, and obesity; stress and other biobehavioral processes; nutrigenomics; health disparities; cancer survivorship; vaccines and immunoprevention; chemoprevention challenges in the era of molecular targeting; and much more. Many sessions will integrate the key disciplines of clinical, behavioral, animal model, and epidemiologic research.
A special forum this year, chaired by Dr. Waun Ki Hong, will focus on professional advancement and mentoring of young investigators in cancer prevention through panel and roundtable discussions with leaders in the field. Educational sessions include, among others, a first-time session on the role of primary care physicians in cancer prevention research and practice as well as a session on “omics” technologies in population-based studies.
We wish to express our gratitude to the National Cancer Institute, NIH, HHS; AstraZeneca; Eli Lilly and Company; Merck; AFLAC, Inc.; the American Cancer Society; Avon Foundation; Comprehensive Minority Biomedical Branch of the National Cancer Institute; and AACR-Women in Cancer Research for their support of this educational activity. We would also like to thank the Cancer Research and Prevention Foundation for their continued support of the AACR-Cancer Research and Prevention Foundation Award for Excellence in Cancer Research. Without the generous support of these organizations, this exciting scientific event would not be possible.
This popular Frontiers Conference fosters collaborations between all the disciplines of prevention research; promotes public, academic, government, and industry awareness of the vital importance of cancer prevention science in reducing cancer incidence and mortality; and catalyzes coordinated, focused, transdisciplinary research efforts that promise to accelerate the contributions of cancer prevention to science and the public health. We trust that the exciting information offered at this conference will benefit the work of investigators in every prevention specialty and at every level of career development.